Follow-The-Filings

Security · featured owners

RYTM Rhythm Pharmaceuticals Inc.

COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 1.2%
  • $36M
  • 1 new 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 1.2% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman reduce 1.2%
  2. Stanley Druckenmiller new 0.43%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.43% New 0.43% 203,618 $23M history
James Silverman - Opaleye Management 2026 Q2 1.2% Reduce −0.4% 122,500 $14M history

2 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $77.43M $130.13M $189.76M
Gross profit * $68.13M $116.76M $170.26M
Gross margin * 88.0% 89.7% 89.7%
Net income -$184.68M -$260.6M -$196.54M
Net margin * -238.5% -200.3% -103.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $308.27M $374.2M $466.92M
Total non-current assets * $24.48M $18.07M $13.28M
Total assets $332.74M $392.27M $480.2M
Total current liabilities $55.2M $115.52M $105.94M
Total non-current liabilities * $107.78M $112.21M $104.23M
Total equity $169.76M $21.73M $139.07M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$136.16M -$113.88M -$115.68M
Cash from investing -$5.66M -$48.17M -$137.15M
Cash from financing $74.37M $191.24M $217.96M
Net change in cash -$67.6M $29.19M -$34.78M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders